The puretech story, where Roche considered the exosomes from mere milk compelling enough to participate in a $1bil collaboration, underpin that there is real potential legs to this biotech genre imho EX1 may surprise themselves - yes partnering would bring a capital/ ‘ market cap’ sugar hit... but just quietly i would rather this stay under the radar to be able to quietly accumulate whilst each product comes to market. I think the results will surprise even the company management
EX1 Price at posting:
69.0¢ Sentiment: Buy Disclosure: Held
